Table 4.
FDA-approved AD Medication use by clinic setting
| Medication | Total patients | African American | Non-Hispanic white | p |
| Enterprise-wide outpatients | ||||
| AD/MCI patients | 3,072 | 651 | 2,421 | |
| Donepezil | 1,243 (40.5%) | 231 (35.5%) | 1,012 (41.8%) | 0.0035 |
| Memantine | 592 (19.3%) | 81 (12.4%) | 511 (21.1%) | <0.0001 |
| Any AD medication | 1,607 (52.3%) | 277 (42.5%) | 1,330 (54.9%) | <0.0001 |
| Memory Disorders | ||||
| AD/MCI patients | 1,047 | 151 | 896 | |
| Donepezil | 565 (54.0%) | 83 (55.0%) | 482 (53.7%) | 0.85 |
| Memantine | 291 (27.8%) | 25 (16.6%) | 266 (29.7%) | 0.0008 |
| Any AD medication | 724 (69.1%) | 96 (63.6%) | 628 (70.1%) | 0.12 |
| Other Neurology | ||||
| AD/MCI patients | 783 | 112 | 671 | |
| Donepezil | 175 (22.3%) | 28 (25.0%) | 147 (21.9%) | 0.46 |
| Memantine | 68 (8.7%) | 5 (4.5%) | 63 (9.4%) | 0.10 |
| Any AD medication | 249 (31.8%) | 32 (28.6%) | 217 (32.3%) | 0.44 |
| Primary Medicine | ||||
| AD/MCI patients | 311 | 149 | 162 | |
| Donepezil | 106 (34.1%) | 46 (30.9%) | 60 (37.0%) | 0.28 |
| Memantine | 41 (13.2%) | 14 (9.4%) | 27 (16.7%) | 0.066 |
| Any AD medication | 122 (39.2%) | 52 (34.9%) | 70 (43.2%) | 0.16 |
| Geriatrics | ||||
| AD/MCI patients | 616 | 196 | 420 | |
| Donepezil | 225 (36.5%) | 64 (32.7%) | 161 (38.3%) | 0.18 |
| Memantine | 124 (20.1%) | 27 (13.8%) | 97 (23.1%) | 0.0070 |
| Any AD medication | 302 (49.0%) | 83 (42.3%) | 219 (52.1%) | 0.024 |
Data presented as counts (percentages) with patient percentages taken out of racial subset total for each clinic setting; p values taken from conditional maximum likelihood exact tests comparing African American proportions to non-Hispanic white proportions within each clinical setting. Any AD medication includes donepezil, rivastigmine, galantamine, or memantine. AD, Alzheimer’s disease; MCI, mild cognitive impairment.